Relationship between CSF neurotransmitter metabolites and aggressive behavior in Alzheimer's disease

European Journal of Neurology

Volumn 3, Issue 2, 1996, Pages 153-155

  Lopez, O L ^a,b   Kaufer, D ^a   Reiter, C T ^a   Carra, J ^a   DeKosky, S T ^a   Palmer, A M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Neuropsychological Research Program   (United States)

Author keywords

5 HIAA; Aggression; Alzheimer's disease; CSF; HVA

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; HOMOVANILLIC ACID; NEUROTRANSMITTER;

ADULT; AGED; AGGRESSION; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METABOLITE; NEUROCHEMISTRY; PRIORITY JOURNAL;

EID: 0029922302     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1996.tb00209.x     Document Type: Article

References (11)

1. Becker JT, Boller F, Lopez OL, Saxton J and McGonigle K (1994) The natural history of Alzheimer's disease. Description of study cohort and accuracy of diagnosis. Archives of Neurology, 51, 585-594.
2. Campbell RJ (1989) Psychiatric Dictionary (6th edn), pp. 20-21. Oxford University Press, New York.
3. Hamilton M (1967) Development of scale for primary depres-sive illness. British Journal of Social Psychology, 6, 278-296.
4. Mattis S (1976) Mental status examination for organic mental syndrome in the elderly patient. In: Geriatric Psychiatry. A Handbook for Psychiatrist's and Primary Care Physician's (Eds L Bellak and TB Karasu), pp. 77-121. Grune and Stratton, New York.
5. Mezzich JE, Dow JT and Cottman GA (1981) Developing an information system for a comprehensive psychiatric institute. I: Principles, design, and organization. Journal of Behavioral Research and Methodological Instrumentation, 13, 459-463.
6. Palmer AM, Sims NR, Bowen DM, Neary D, Palo J, Wikstrom J and Davidson A (1984) Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. Journal of Neurology, Neurosurgery and Psychiatry, 47, 481-484.
7. Palmer AM, Benton FJS, Sims NR, Mann DMA, Neary D, Snowden JS and Bowen DM (1987a) Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. Journal of Neurochemistry, 48, 8-15.
8. Palmer AM, Wilcock GK, Esiri MM, Francis PT and Bowen DM (1987b) Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Research, 401, 221-238.
9. Palmer AM, Stratmann GC, Procter AW and Bowen DM (1988) Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Annals of Neurology, 23, 616-620.
10. Procter AW, Francis PT, Stratmann GC and Bowen DM (1992) Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochemistry Research, 17, 917-922.
11. Schneider LS and Sobin PB (1991) Non-neuroleptic medication in the management of agitation in Alzheimer's disease and other dementia: a selective review. International Journal of Geriatric Psychiatry, 6, 691-708.